Akin Akinc

Active 2002–2024

41
Papers
23,887
Citations
39
h-index
40
i10-index

Citations

Citations per year for Akin Akinc1989: 1 citations1994: 4 citations2002: 2 citations2003: 3 citations2004: 17 citations2005: 68 citations2006: 132 citations2007: 173 citations2008: 188 citations2009: 220 citations2010: 219 citations2011: 268 citations2012: 337 citations2013: 267 citations2014: 310 citations2015: 342 citations2016: 353 citations2017: 293 citations2018: 391 citations2019: 879 citations2020: 1,038 citations2021: 1,190 citations2022: 1,121 citations2023: 1,095 citations2024: 1,475 citations2025: 908 citations2026: 28 citations1990–1993: no citations, so these years are not shown1995–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,803 citing papers, 28.9% of this breakdownChina: 1,405 citing papers, 14.5% of this breakdownGermany: 506 citing papers, 5.2% of this breakdownUnited Kingdom: 441 citing papers, 4.6% of this breakdownCanada: 425 citing papers, 4.4% of this breakdownJapan: 326 citing papers, 3.4% of this breakdownFrance: 244 citing papers, 2.5% of this breakdownAustralia: 240 citing papers, 2.5% of this breakdownSouth Korea: 237 citing papers, 2.4% of this breakdownItaly: 235 citing papers, 2.4% of this breakdownNetherlands: 232 citing papers, 2.4% of this breakdownIndia: 227 citing papers, 2.3% of this breakdown
0%28.9%Other 24.5%

Fields

  • Biochemistry, Genetics and Molecular Biology69%
  • Medicine15.7%
  • Materials Science6.2%
  • Immunology and Microbiology3.8%
  • Engineering2.2%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Other2.3%

Topics

  • RNA Interference and Gene Delivery20.5%
  • Advanced biosensing and bioanalysis techniques12.2%
  • MicroRNA in disease regulation4.8%
  • Nanoparticle-Based Drug Delivery4.1%
  • Virus-based gene therapy research3.7%
  • Immunotherapy and Immune Responses2.7%
  • Other52%

Coauthors

All papers

Open in search
  1. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

    Authors: , , , , , , , , , , , , , , , , , - Nature Nanotechnology 2019 cited by 1,569

  2. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Biotechnology 2013 cited by 1,576

  3. Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

    Authors: , , , , , , , , , , , , , , , , , , - Angewandte Chemie 2012 cited by 1,221

  4. Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Therapy 2010 cited by 1,215

  5. Rational design of cationic lipids for siRNA delivery

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Verbena Kosovrasti, William Cantley, Ying K. Tam, Muthiah Manoharan, Marco A. Ciufolini, Mark A. Tracy, Antonin de Fougerolles, Ian MacLachlan, Pieter R. Cullis, Thomas D. Madden, Michael J. Hope - Nature Biotechnology 2010 cited by 1,779

  6. Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Therapy 2013 cited by 619

  7. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles

    Authors: , , , , , , , , , , , , , , , - Molecular Therapy — Nucleic Acids 2013 cited by 482

  8. Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Chemical Society 2014 cited by 1,078

  9. Lipid-like materials for low-dose, in vivo gene silencing

    Authors: , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 965

  10. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Róbert Langer, Daniel G. Anderson - Nature Biotechnology 2008 cited by 1,220

  11. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 481

  12. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Klaus Charissé, Mark W. Kieran, Kevin Fitzgerald, Matthias Nahrendorf, Dganit Danino, Rubin M. Tuder, Ulrich H. von Andrian, Akin Akinc, Dipak Panigrahy, Avi Schroeder, Victor Koteliansky, Róbert Langer, Daniel G. Anderson - Nature Nanotechnology 2014 cited by 573

  13. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nucleic Acids Research 2017 cited by 270

  14. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2004 cited by 2,187

  15. MicroRNAs 103 and 107 regulate insulin sensitivity

    Authors: , , , , , , , - Nature 2011 cited by 993

  16. Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy

    Authors: , , , , , , , , , - Molecular Therapy — Nucleic Acids 2014 cited by 217

  17. Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis

    Authors: , , , - The Journal of Gene Medicine 2004 cited by 1,329

  18. RNAi-mediated gene silencing in non-human primates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2006 cited by 1,350

  19. Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver

    Authors: , , , , , , , , , , , , , , - Molecular Therapy 2009 cited by 349

  20. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rodney M. Camire, Akin Akinc - Nature Medicine 2015 cited by 297

  21. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 357

  22. 5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates

    Authors: , , , , , , , , , , , , , , , , , , - ChemBioChem 2016 cited by 137

  23. Reversal of siRNA-mediated gene silencing in vivo

    Authors: , , , , , , , , , , , , , , , - Nature Biotechnology 2018 cited by 92

  24. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor Koteliansky, Jay D. Horton, Kevin Fitzgerald - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 639